Two Biotech Firms Get Back Drug Rights | Chemical & Engineering News
Volume 89 Issue 37 | p. 13 | Concentrates
Issue Date: September 12, 2011

Two Biotech Firms Get Back Drug Rights

Department: Business
News Channels: Biological SCENE
Keywords: drug discovery, Parkinson’s, muscular dystrophy

Citing portfolio reassessment, two drug companies are returning pharmaceutical development rights to biotech partners. Merck & Co. has returned Parkinson’s drug candidates to Addex Pharmaceuticals, the Swiss firm that discovered them. Addex says it will continue to develop the drugs, known as allosteric modulators. Genzyme, meanwhile, has returned non-U.S. rights for ataluren, a treatment for muscular dystrophy and cystic fibrosis, to PTC Therapeutics. PTC already had U.S. rights to the drug, which is in clinical trials.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment